Stipple Bio licenses Lonza ADC platform for precision oncology push
Stipple Bio, a private Cambridge, Massachusetts-based biotechnology company, has entered a multi-target licensing agreement with Swiss CDMO giant Lonza to advance a pipeline of antibody-drug conjugate (ADC) therapies in precision oncology. The deal grants Stipple Bio access to Lonza's GlycoConnect antibody conjugation technology, HydraSpace polar spacer, and toxSYN linker-payload system — all components of Lonza's clinically validated ADC platform — starting with Stipple Bio's lead programme, STP-100.
Under the commercial terms, Lonza is eligible to receive upfront payments alongside clinical, regulatory, and commercial milestone payments, plus royalties on net sales. Lonza retains manufacturing responsibility for the proprietary technology components; Stipple Bio leads research, development, and eventual commercialisation of the resulting ADC products. Financial details of the upfront payment were not disclosed.
The science behind the deal
Stipple Bio's differentiation centres on its Pointillist Platform, which the company says identifies tumour-specific cell surface epitopes at a resolution designed to minimise on-target, off-tumour toxicity — one of the field's persistent safety challenges. By combining epitope-level target selection with Lonza's site-specific bioconjugation chemistry, the company is positioning its candidates as potential first-in-class or best-in-class medicines, according to the press release.
Jeff Landau, chief executive of Stipple Bio, described ADCs as "a core pillar of cancer treatment" and said that increasingly sophisticated design was translating into stronger efficacy and reduced off-target effects. He said Lonza's clinically validated platform would be "instrumental" in advancing STP-100, though no trial phase, indication, or clinical timeline was disclosed for the programme.
Jan Vertommen, Lonza's head of commercial development for advanced synthesis, said the collaboration aimed to help Stipple Bio progress "more precise and effective ADC programmes with confidence and speed", citing Lonza's bioconjugation and scalable manufacturing capabilities.
Market context
The ADC sector has undergone a significant re-rating over the past three years, driven by a string of late-stage readouts and regulatory approvals — most notably in HER2-positive cancers and urothelial carcinoma — that have validated the modality at commercial scale. That momentum has drawn in virtually every major pharmaceutical company through in-licensing, acquisitions, or internal build-outs, and has simultaneously crowded the target landscape, pushing next-generation developers toward differentiated payload chemistry, novel targets, and improved therapeutic windows.
Lonza's GlycoConnect platform sits within this context as an established, commercially deployed technology: it has featured in ADC programmes that have advanced to clinical trials with other partners, giving Stipple Bio a degree of de-risking on the manufacturing and conjugation side. For a private company at an early stage, access to a validated CDMO platform can compress the time from molecule design to IND-enabling studies.
Stipple Bio has not yet disclosed the target antigen for STP-100, nor the tumour type it intends to address first. As the ADC field grows more competitive, the credibility of the epitope-selection rationale and the differentiation of the lead target will be the key questions investors and potential partners are likely to press on when the company next seeks capital or a co-development arrangement.